Skip to content

Clinical study on Transcutaneous Auricular Vagus Nerve Stimulation in The Treatment of Post-stroke Cognitive Impairment

Clinical study on Transcutaneous Auricular Vagus Nerve Stimulation in The Treatment of Post-stroke Cognitive Impairment

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057808
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-03-20
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke cognitive impairment

Interventions

Sponsors

The First Affiliated Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50-70 years old; 2. Patients meeting the diagnostic criteria of traditional Chinese and western medicine for ischemic stroke, 2-4 weeks after the occurrence of stroke event; 3. Patients with the first stroke and NIHSS score of 5-15; 4. Patients With cognitive impairment, MoCA score <=26, MMSE score <=26; 5. Patients who were conscious and had no serious aphasia or intelligence disorder, and could communicate normally and complete the scale evaluation; 6. Agree and voluntarily participate in the clinical study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with diseases related to cognitive impairment, such as epilepsy, Parkinson's disease, Alzheimer's disease, or cognitive impairment prior to stroke events; 2. Accompanied by serious mental diseases such as depression, schizophrenia which may affect the evaluation of cognitive function; 3. Patients with serious heart, liver, kidney, or blood diseases, which are not suitable for the intervention of this study; 4. Auricle malformation, injury, or ulceration, which cannot be interfered with Transcutaneous Auricular Vagus Nerve Stimulation; 5. Electronic devices implanted in the body (such as pacemakers, cochlear implants, etc.); 6. Participating in other clinical trials that conflict with or interact with this study.

Design outcomes

Primary

MeasureTime frame
The Montreal Cognitive Assessment;Minimum Mental State Examination;

Secondary

MeasureTime frame
Activity of daily living scale;Hamilton anxiety scale;

Countries

China

Contacts

Public ContactZhendong Li

The First Affiliated Hospital of Hunan University of Chinese Medicine

zhangyuejuanhuli@163.com+86 15225153153

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026